Evidence map›Paper›PMID 37520727›Full record

ArticleiScience2023

Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia.

Diana Cadena Castaneda, Sonia Jangra, Marina Yurieva, Jan Martinek, Megan Callender, Matthew Coxe, Angela Choi, Juan García-Bernalt Diego, Jianan Lin, Te-Chia Wu and 14 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 1 country.

Diana Cadena CastanedaThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Marina YurievaThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Jan MartinekThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Megan CallenderThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Matthew CoxeThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Angela ChoiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Juan García-Bernalt DiegoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jianan LinThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Te-Chia WuThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Florentina MarchesThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Damien ChaussabelThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Peter YuHartford HealthCare Cancer Institute, Hartford, CT 06102, USA.
Andrew SalnerHartford HealthCare Cancer Institute, Hartford, CT 06102, USA.
Gabrielle AucelloThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Jonathan KoffAdult Cystic Fibrosis Program, Yale University, New Haven, CT 06519, USA.
Briana HudsonNanostring Technologies, Translational Sciences, Seattle, WA 98109, USA.
Sarah E ChurchNanostring Technologies, Translational Sciences, Seattle, WA 98109, USA.
Kara GormanNanostring Technologies, Translational Sciences, Seattle, WA 98109, USA.
Esperanza AnguianoNanostring Technologies, Translational Sciences, Seattle, WA 98109, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Adam WilliamsThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Karolina PaluckaThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Jackson Laboratory · USIcahn School of Medicine at Mount Sinai · USNanostring Technologies (United States) · USHartford Financial Services (United States)Tisch Hospital · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Paul Robson · 1985 to 2026
$61.9M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
Technology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Damien Chaussabel · 2019 to 2026
$23.1M
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody AnalysesU54CA260560 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO, HIRSCH, FRED R · 2020 to 2024
$10.0M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
lncRNA Control of Airway Epithelial Cell Responses to Type 2 InflammationR01AI141609 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WILLIAMS, ADAM · 2019 to 2022
$2.4M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA034196NCI NIH HHS U54 CA260560NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI141609NIAID NIH HHS R01 AI160706NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI142733NIDDK NIH HHS R01 DK130425
6 · The paper itself

Abstract

The COVID-19 pandemic continues to be a health crisis with major unmet medical needs. The early responses from airway epithelial cells, the first target of the virus regulating the progression toward severe disease, are not fully understood. Primary human air-liquid interface cultures representing the broncho-alveolar epithelia were used to study the kinetics and dynamics of SARS-CoV-2 variants infection. The infection measured by nucleoprotein expression, was a late event appearing between day 4-6 post infection for Wuhan-like virus. Other variants demonstrated increasingly accelerated timelines of infection. All variants triggered similar transcriptional signatures, an "early" inflammatory/immune signature preceding a "late" type I/III IFN, but differences in the quality and kinetics were found, consistent with the timing of nucleoprotein expression. Response to virus was spatially organized: CSF3 expression in basal cells and CCL20 in apical cells. Thus, SARS-CoV-2 virus triggers specific responses modulated over time to engage different arms of immune response.

Indexed as

biological sciencesImmunologyMicrobiologymolecular biology

Identifiers

PMID37520727
PMCPMC10374611
OpenAlexW4384007253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.